At the intersection of endocrinology and microbiology, researchers at Cedars-Sinai Medical Center have illuminated a quiet but consequential relationship between the thyroid gland and the gut — two systems long treated as strangers. Presented at the Endocrine Society's annual conference in San Francisco, their findings suggest that an underactive thyroid more than doubles the risk of small intestinal bacterial overgrowth, while the hormone therapy already prescribed to millions appears to offer protection. In medicine, as in most human endeavors, the boundaries we draw between systems often sa
Underactive thyroid linked to doubled SIBO risk, treatable with hormone therapy
Cobertura Relacionada
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
This is a medical research article about thyroid disease and gut health, not a geopolitical matter.
Lente Econômica
Research links hypothyroidism to 2.2-2.4x higher SIBO risk, treatable with hormone therapy, potentially expanding thyroid medication market and diagnostic testing demand.
Consumers with hypothyroidism may face increased healthcare costs from additional SIBO screening and testing, but could benefit from improved treatment outcomes and reduced gastrointestinal complications through optimized thyroid hormone therapy.
Potential for updated clinical guidelines recommending SIBO screening in hypothyroidism patients; possible insurance coverage expansion for diagnostic testing; increased R&D investment in personalized microbiome-based treatments; regulatory focus on thyroid hormone therapy optimization protocols.